CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

Mary E. Klein, Marta Kovatcheva, Lara Davis, William D. Tap, Andrew Koff

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to understand the cellular mechanisms by which they act. Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future.

Original languageEnglish (US)
Pages (from-to)9-20
Number of pages12
JournalCancer Cell
Volume34
Issue number1
DOIs
StatePublished - Jul 9 2018

Fingerprint

letrozole
Hormone Antagonists
Cytostatic Agents
Appointments and Schedules
Clinical Trials
Breast Neoplasms
Growth
Neoplasms
Therapeutics

Keywords

  • abemaciclib
  • CDK4/6 inhibitors
  • metabolism
  • palbociclib
  • ribociclib
  • senescence
  • tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

CDK4/6 Inhibitors : The Mechanism of Action May Not Be as Simple as Once Thought. / Klein, Mary E.; Kovatcheva, Marta; Davis, Lara; Tap, William D.; Koff, Andrew.

In: Cancer Cell, Vol. 34, No. 1, 09.07.2018, p. 9-20.

Research output: Contribution to journalReview article

Klein, Mary E. ; Kovatcheva, Marta ; Davis, Lara ; Tap, William D. ; Koff, Andrew. / CDK4/6 Inhibitors : The Mechanism of Action May Not Be as Simple as Once Thought. In: Cancer Cell. 2018 ; Vol. 34, No. 1. pp. 9-20.
@article{a31b2431a727454e8f9543aad330451e,
title = "CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought",
abstract = "CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to understand the cellular mechanisms by which they act. Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future.",
keywords = "abemaciclib, CDK4/6 inhibitors, metabolism, palbociclib, ribociclib, senescence, tumor microenvironment",
author = "Klein, {Mary E.} and Marta Kovatcheva and Lara Davis and Tap, {William D.} and Andrew Koff",
year = "2018",
month = "7",
day = "9",
doi = "10.1016/j.ccell.2018.03.023",
language = "English (US)",
volume = "34",
pages = "9--20",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - CDK4/6 Inhibitors

T2 - The Mechanism of Action May Not Be as Simple as Once Thought

AU - Klein, Mary E.

AU - Kovatcheva, Marta

AU - Davis, Lara

AU - Tap, William D.

AU - Koff, Andrew

PY - 2018/7/9

Y1 - 2018/7/9

N2 - CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to understand the cellular mechanisms by which they act. Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future.

AB - CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to understand the cellular mechanisms by which they act. Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future.

KW - abemaciclib

KW - CDK4/6 inhibitors

KW - metabolism

KW - palbociclib

KW - ribociclib

KW - senescence

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85045100114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045100114&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2018.03.023

DO - 10.1016/j.ccell.2018.03.023

M3 - Review article

C2 - 29731395

AN - SCOPUS:85045100114

VL - 34

SP - 9

EP - 20

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 1

ER -